To view original article click here
CTVNews.ca Staff: Avis FavaroCTV National News Medical Correspondent, @ctv_avisfavaro, Elizabeth St. PhilipCTV News, @LizTV, Mariam MattiCTVNews.ca Writer, @mariammatti
Published Saturday, January 11, 2020 10:00PM EST
The study, published in the Journal of Child and Adolescent Psychopharmacology, analyzed data collected from 2012 to 2016 for youths under 18. Over the five-year period, Calgary researchers found that prescribing of antidepressants in that age group rose by 36 per cent, from 120 per 100,000 to 160 per 100,000people.
Antidepressant Fluoxetine was the most commonly recommended drug, according to the study.
Co-author Dr. Scott Patten told CTV News that he was “a little” surprised by the results. Most surprising was a 114 per cent rise in prescribing of an older class of medications tricyclic antidepressants, which carry a risk of cardiovascular problems.
“We’ve also looked at the issue of if prevalence of depression is increasing in this age group and we haven’t found evidence that it is so we didn’t expect to see an increase in prescription of these medications,” says Patten, a professor at the Cumming School of Medicine in Calgary.
For youth aged 13 to 18, depression was most commonly associated with antidepressant prescriptions, while anxiety disorder was mostly linked to prescriptions among the other age groups.
While the study shows an increase in prescribing of antidepressants, Health Canada has never officially approved the medications for anyone under 18. Some doctors will use a method called off-label to prescribe antidepressants to young people.
The researchers used a survey administered to 652 physicians in Canada by a database called the Canadian Disease and Therapeutic Index (CDTI).
Patten says their study raises some important questions they were unable to answer.
“The data source that we used limits our ability to interpret the trend,” he said. “It should provide strong motivation for more detailed studies using perhaps different methods that would be able to better understand why we’re seeing this increase in antidepressant recommendations.”
A possible explanation for why more young people are using antidepressants is that the stigma around mental health illness has decreased over time, which could lead to more people seeking treatment, according to Patten.
There also seems to be better mental health literacy among adolescents. “The trend we saw might reflect that,” he says.
“It’s conceivable if there are inadequate resources available for people to receive psychotherapy, they may end up receiving pharmacotherapy instead,” says Patten. “Generally, in this age range, the preferred first option for treatment of depression is psychotherapy.”
Mina Tadrous, a scientist with Women’s College Research Institute in Toronto, says it’s possible that some of the medications are being used for other conditions – such as autism, sleep problems or muscle pain.
“We continue to see a rise in the use of this medication, and we need more research to see if this is a good or bad thing, or as I suspect, a bit of both,” Tadrous told CTV News.
Patten thinks “we have to be careful in assuming that the increase is entirely a negative thing.”
“Historically, there has been an underutilization of mental health services. Psychotherapy is the best option for some people, while medication is the best option for other people,” he said. “We don’t want to stigmatize or vilify these medications. We want them to be used in the manner that is the most consistent with achieving the best possible outcome for people.”
Patten says his team is planning additional research as a follow up.
To view complete original study, results click here
Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children — (Journal of Child and Adolescent Psychopharmacology Vol. 30, No. 6)
Aysha Lukmanj, Tamara Pringsheim, Andrew G. Bulloch, David G. Stewart, Parco Chan, Ali Tehrani, and Scott B. Patten
Objective: Few studies have longitudinally followed trends in antidepressant prescribing for Canadian children following the Black Box warning issued in 2004. Using a national data source, we aim to describe trends in antidepressant recommendations for Canadian children ages 1–18 during 2012 to 2016.
Methods: A database called the Canadian Disease and Therapeutic Index (CDTI), provided by IQVIA, was used to conduct analyses. The CDTI dataset collects a quarterly sample of pediatric antidepressant recommendations, projected using a weight procedure from a dynamic sample of 652 Canadian office-based physicians. The term “recommendations” is used because nonprescription drugs may be recommended and there is no confirmation in the database that the prescriptions were filled or medications taken. The data were collected from 2012 to 2016 and the sample population was projected by IQVIA to be representative of the entire Canadian pediatric population.
Results: The total number of projected antidepressant recommendations for children increased from 2012 to 2016. Selective serotonin reuptake inhibitors were the most recommended class of antidepressants. Analysis indicated that fluoxetine was the most frequently recommended drug. Findings also suggest that recommendations for tricyclic antidepressants (TCAs) are increasing, but predominantly for reasons other than treatment of depression.
Conclusions: Overall, antidepressant use in Canadian children increased over the study period. Unsurprisingly, fluoxetine was the most recommended antidepressant for Canadian children. However, the observed increase in TCA use for a pediatric population is unexpected. The data source is descriptive and lacks detailed measures supporting comprehensive explanation of the findings, therefore, further research is required.